The disclosure relates to novel C4 and C6 substituted androst-4-ene diones as well as andros-1 4-diene diones and derivatives thereof their process of preparation pharmaceutical compounds containing them and the use of said compounds for the treatment of hormone-related disorders in mammals. This includes hormone-dependent cancers particularly those caused by elevated levels of estrogen and its intermediates. These compounds can also be used in the treatment of other hormone-related disorders including benign prostatic hyperplasia cardiovascular disease and neurodegenerative disorders.
